-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $10

Benzinga·04/10/2026 09:41:26
Listen to the news
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $22 to $10.